Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: J Cereb Blood Flow Metab. 2009 May 20;29(8):1373–1382. doi: 10.1038/jcbfm.2009.68

Figure 5. Therapeutic efficacy of DMXAA against gliomas.

Figure 5

Kaplan-Meier survival analysis of GL261 (A) and U87 glioma-bearing animals (B) treated with a single dose of DMXAA (30 mg/kg – GL261; 27.5 mg/kg – U87). Differences in median survival between animals in the control and treatment groups were analyzed for statistical significance using the log-rank test. Control vs treatment groups: p=0.0028 (GL261; Controls n=12; DMXAA n=6) and p=0.0005 (U87; Controls n=13; DMXAA n=10).